艾迪亚生物科技 IDYA

Effective June 16, 2026, the Company's Board of Directors elected Yujiro S. Hata as Chairman of the Board. Yujiro S. Hata has served as a member of our board of directors and as our President and Chief Executive Officer since June 2015. He launched IDEAYA Biosciences, Inc. as its first employee and Chief Executive Officer, while serving as an Executive-in-Residence at 5AM Ventures, a venture capital firm, from 2015 to 2018. From 2014 to August 2015, he served as Chief Operating Officer at Flexus Biosciences, Inc. and FLX Bio, Inc. (renamed RAPT Therapeutics), both immuno-oncology companies, which he joined as startups and led through Flexus' acquisition by Bristol-Myers Squibb Co. in April 2015. From 2010 to 2014, including through its acquisition by Amgen Inc. in October 2013, he was Vice President, Corporate Development and Strategy at Onyx Pharmaceuticals, Inc. where he served as Head of Strategy and Strategic Asset Management, and Head of Transactions. From 2002 to 2010, Mr. Hata served as Vice President and Senior Vice President of Business Development, and Chief Business Officer at Enanta Pharmaceuticals, Inc. He earlier served in roles at McKinsey & Company, ImClone Systems Incorporated, and Columbia Medical School. Mr. Hata serves on the board of directors at Enanta Pharmaceuticals, Inc. and Hexagon Bio, Inc. Mr. Hata obtained an M.B.A. at The Wharton School at the University of Pennsylvania and a B.A. in Chemistry from Colorado College.

Joshua Bleharski, Ph.D. has served as our Chief Financial Officer since May 2025 and as our principal financial officer since June 2025. Dr. Bleharski spent nearly 17 years with J.P. Morgan, where he was a Managing Director and Global Co-Head of Biopharma within the Healthcare Investment Banking group. Over the course of his banking career Dr. Bleharski advised on deals representing more than $65 billion of value, with a focus on capital markets transactions, mergers and acquisitions, and corporate strategy. Prior to J.P. Morgan, Dr. Bleharski worked as a Senior Staff Scientist at a private biotechnology company in San Diego and was a post-doctoral fellow at the La Jolla Institute for Allergy and Immunology and the UCLA School of Medicine. Dr. Bleharski received his M.B.A. from the Haas School of Business at the University of California, Berkeley, Ph.D. in immunology from the University of California, Los Angeles and B.S. in biology from Duke University.

Darrin M. Beaupre, M.D., Ph.D. has served as our Chief Medical Officer since November 2022. From November 2020 to November 2022, Dr. Beaupre served as Chief Medical Officer with Biosplice Therapeutics, Inc., a biopharmaceutical company. From February 2017 to November 2020, Dr. Beaupre was Senior Vice President, Early Oncology Development and Clinical Research, at Pfizer Inc., a pharmaceutical and biotechnology company. From October 2012 to February 2017, Dr. Beaupre was with Pharmacyclics, Inc, a biotechnology company, in various capacities including as Head of Early Development and Immunotherapy. From October 2006 to October 2012, Dr. Beaupre was a Medical Director at Amgen Inc., a pharmaceutical and biotechnology company. Dr. Beaupre also taught medicine at the H. Lee Moffitt Cancer Center and Research Institute and the University of Miami. He received his M.D. and Ph.D. in Cancer Biology at the University of Texas at Houston and MD Anderson Cancer Center, respectively, where he was a member of the MD PhD program. Dr. Beaupre obtained his M.S. and B.S. in Biological Sciences from the University of Lowell.

Michael A. White, Ph.D. has served as our Chief Scientific Officer since October 2021. From April 2020 to October 2021, Dr. White served as Chief Scientific Officer of Biosplice Therapeutics, Inc. a biopharmaceutical company. From April 2016 to April 2020, Dr. White served as Chief Scientific Officer and Head of Tumor Biology at Pfizer Inc., a pharmaceutical and biotechnology company. From 1995 to 2016, Dr. White was at UT Southwestern Medical Center where he was a Professor of Cell Biology and founding Director of the Cancer Intervention and Prevention Discovery Program. Dr. White obtained his Ph.D. in Biology from the University of North Carolina at Chapel Hill and afterward completed his postdoctoral fellowship in Biology at Cold Springs Harbor Laboratory. Dr. White obtained his B.S. in Biology from the University of Iowa.

Andres Ruiz Briseno has served as our Chief Accounting Officer since March 2025 and as our principal accounting officer since July 2023. He served as our principal financial officer from December 2023 to June 2025. He served as our Senior Vice President, Head of Finance and Investor Relations from July 2023 to February 2025. From November 2021 to June 2023, he served as our Vice President, Head of Business Operations and Investor Relations. From July 2021 to October 2021, Mr. Briseno was Senior Vice President, Finance & Principal Accounting Officer at Neumora Therapeutics, a biotechnology company. Previously, he held roles at IDEAYA from August 2016 to July 2021, including most recently as Vice President, Finance. Prior to joining the Company in 2016, Mr. Briseno held several roles at Pharmacyclics, Inc., including as Associate Director, Financial Planning and Analysis. Prior to that, Mr. Briseno held roles at Theravance, Inc., and in PricewaterhouseCoopers' audit and assurance practice where he focused on life science and venture capital clients. Mr. Briseno obtained his B.S. in Business Administration with a concentration in Corporate Financial Management from San Jose State University and is a Certified Public Accountant, licensed in the state of California.

Effective June 16, 2026, the Company's Board of Directors elected Terry J. Rosen, Ph.D as the Board's Lead Independent Director. has served as a member of our board of directors since January 2016 and chairperson of our board of directors since June 2023. Dr. Rosen currently serves on the board of directors and as the Chief Executive Officer of Arcus Biosciences, Inc., a biopharmaceutical company, positions he has held since April 2015 and May 2015, respectively. He served as the Chief Executive Officer of PACT Pharma, Inc., a biopharmaceutical company, from November 2016 to December 2017. Dr. Rosen served briefly in April 2015 as the Chief Executive Officer of FLX Bio (renamed RAPT Therapeutics). Previously, Dr. Rosen co-founded and served as the Chief Executive Officer of Flexus from October 2013 to April 2015, when it was acquired by Bristol-Myers Squibb. Prior to that, Dr. Rosen was at Amgen from August 2004 to January 2013 where he most recently served as Vice President of Therapeutic Discovery from November 2011 to January 2013. He also worked at Tularik Inc., from October 1993 to August 2004 when it was acquired by Amgen, the Central Research division of Pfizer Inc., or Pfizer, from December 1987 to September 1993, and Abbott Laboratories, from July 1985 to December 1987. Dr. Rosen holds a Ph.D. in Chemistry from the University of California, Berkeley and a B.S. in Chemistry from the University of Michigan.

Scott W. Morrison has served as a member of our board of directors since July 2018. From 1996 to December 2015, Mr. Morrison was a partner with Ernst & Young LLP, a public accounting firm, where he also served as U.S. Life Sciences Leader from 2002 to December 2015. Mr. Morrison currently serves on the board of directors of Vera Therapeutics, Inc., Tarsus Pharmaceuticals and Zai Lab Limited. He previously served on the board of directors of Corvus Pharmaceuticals, Inc. Mr. Morrison holds a B.S. in Business Administration from the University of California, Berkeley. He is a Certified Public Accountant (inactive).

Wendy L. Yarno has served as a member of our board of directors since December 2019. Ms. Yarno retired in September 2008 from Merck & Co, Inc. where she spent 26 years in commercial and human resource positions of increasing seniority, including most recently as Executive Vice President and Chief Marketing Officer. She previously served as General Manager, Cardiovascular / Metabolic U.S. Business Unit and as Executive Vice President, Worldwide Human Health Marketing. From 2010 to 2011, Ms. Yarno was the Chief Marketing Officer of HemoShear LLC, a biotechnology research company. Ms. Yarno currently serves on the board of directors of publicly traded life sciences companies Inovio Pharmaceuticals, Inc., Iovance Biotherapeutics, Inc. and Tarsus Pharmaceuticals, Inc. On March 17, 2026, Ms. Yarno informed Iovance Biotherapeutics she will be retiring from their board of directors at their annual meeting of stockholders currently anticipated to take place in June 2026. She previously served on the board of directors of various other life science companies, including Global Blood Therapeutics, Alder Biopharmaceuticals, Durata Therapeutics, St. Jude Medical, Medivation and MyoKardia. Ms. Yarno received an M.B.A. from Temple University, Fox School of Business, and a B.S. in business administration from Portland State University.

Catherine J. Mackey, Ph.D. has served as a member of our board of directors since April 2022. Dr. Mackey previously served as Senior Vice President of Pfizer Worldwide Research and Development and Director of Pfizer's La Jolla Laboratories, where she built Pfizer La Jolla into one of Pfizer's main pharmaceutical research and development sites. Prior to that role, she served as head of Strategic Alliances and Genomic and Proteomic Sciences for Pfizer. Dr. Mackey spent the first part of her career in agricultural biotechnology, including as Vice President of DEKALB Genetics, Inc., an international researcher, producer, and marketer of seed. Dr. Mackey serves on the board of directors of Voyager Therapeutics, a gene therapy and neurology biotechnology company, and previously served on the board of directors of Avid Bioservices, a commercial biologics contract development and manufacturing company. Dr. Mackey received her B.S. and Ph.D. degrees in microbiology from Cornell University.

M. Garret Hampton, Ph.D. has served as a member of our board of directors since June 2020. From June 2020 to September 2024, Dr. Hampton served as President, Clinical Sequencing and Oncology at Thermo Fisher Scientific, responsible for leading the company's clinical next generation sequencing strategy. Prior to Thermo Fisher, from January 2017 to January 2020, Dr. Hampton was Senior Vice President, Clinical Genomics, at Illumina, Inc., responsible for the development of sequencing-based solutions in oncology, reproductive health and whole genome sequencing for the diagnosis of rare disease. From June 2009 to December 2016, Dr. Hampton worked for Genentech, Inc., as Vice President and Global Head of Oncology Biomarker Development and Companion Diagnostics. Before joining Genentech, Dr. Hampton held a variety of leadership positions at Celgene and The Genomics Institute of the Novartis Research Foundation, focused on drug target discovery, drug development and precision medicine. Before moving into industry, Dr. Hampton was Assistant Professor of Medicine at University of California, San Diego after a 2-year postdoctoral fellowship at the Salk Institute for Biological Studies. Dr. Hampton received his Ph.D. from the Imperial Cancer Research Fund (now Cancer Research UK) under Sir Walter Bodmer. He has authored over 150 peer reviewed articles and reviews, with 10,000 lifetime citations.

Stuart C. Dorman has served as our Chief Commercial Officer since December 2024. From October 2020 to November 2024, Mr. Dorman served as Vice President, US Oncology Business Unit Head at Gilead Sciences, a leading biopharmaceutical company. From July 2006 to October 2020, Mr. Dorman held various commercial roles of increasing responsibility, including Vice President of Oncology Worldwide Commercialization at Bristol Myers Squibb, a leading biopharmaceutical company. From 1999 to 2004, Mr. Dorman was a Senior Consultant and Manager at Trinity Partners LLC, a strategy consulting company for the life sciences industry. He obtained his MBA from the Stanford Graduate School of Business and received his AB in Economics from Harvard University.

Douglas B. Snyder has served as our Chief Legal Officer since January 2026. He served as our Senior Vice President, General Counsel from September 2024 to December 2025. From 2017 to 2022, Mr. Snyder served as Executive Vice President, Chief Legal Officer and Secretary to GW Pharmaceuticals, a biopharmaceutical company. From 2012 to 2017, Mr. Snyder served as Senior Vice President, General Counsel, and secretary for Actelion U.S., a pharmaceuticals and biotechnology company. Prior to that, Mr. Snyder held the position of Senior Vice President, General Counsel and Secretary at Eisai Inc., where he led the Legal, Compliance, Legislative Affairs, Internal Audit and Security Group. From 1999-2005, he was vice-president, associate general counsel for GlaxoSmithKline (GSK). During his tenure at GSK, Mr. Snyder managed the legal and communications strategies related to some of GSK's most high-profile matters concerning the New York Attorney General, the U.S. Department of Justice and the FDA. Before joining the pharmaceutical industry, he held the role of Associate General Counsel for the FDA where he counseled the Commissioner, appeared before Congress in key initiatives, and led the initial False Claims/Kickback cases against the pharmaceutical industry.